Results 81 to 90 of about 28,560 (247)
International Journal of General Medicine, 2022 Purpose Pneumocystis jirovecii pneumonia (PCP) is a major cause of death in immunocompromised patients. Many risk factors for poor prognosis have been reported, but few studies have created predictive models with these variables to calculate the death ...
Q. Feng, Jingjing Hao, Ang Li, Z. Tong
semanticscholar +1 more source
, 2017 In humans, Pneumocystis pneumonia is caused by a yeast-like fungus Pneumocystis jirovecii. Originally called P. carinii, this organism was thought to be a protozoan; however, the discovery of chitin, β-1,3-glucan, and ergosterol in the cell wall ...
Stuart Flanagan
core +1 more source
Pathogens, 2021 Pneumocystis jirovecii is a fungal pathogen that can cause life-threatening infections in individuals who are immunocompromised. Acquired via inhalation, upon entering the respiratory tract, the fungi first encounter innate immune cells such as alveolar ...
Theodore J. Kottom +3 more
doaj +1 more source
Transplant Infectious Disease, EarlyView.In a retrospective cohort study of 149 patients receiving atovaquone for PJP prophylaxis, increased usage was related to broader indications, uptake in new patient groups, difficulty tolerating or accessing alternatives, and longer durations used per patient.
To N. Pham +5 more
wiley +1 more source
Journal of Fungi, 2020 Pneumocystis pneumonia (PcP) is a disease produced by the opportunistic infection of the fungus Pneumocystis jirovecii. As delayed or unsuitable treatments increase the risk of mortality, the development of rapid and accurate diagnostic tools for PcP are
Luis Pla +9 more
doaj +1 more source
Case Reports in Pulmonology, 2022 Pneumocystis jirovecii is an opportunistic fungus that is classically associated with pneumonia in immunocompromised patients, particularly those with human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS). However, this infection
Mansur Assaad +2 more
doaj +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson +3 more
wiley +1 more source
Clinical Rheumatology, 2021 To compare Pneumocystis jirovecii pneumonia (PJP) risk between patients with autoimmune rheumatic diseases (ARD) and the general population We identified patients with ARD recorded in the National Health Insurance Research Database of Taiwan from 2002 to
Hui-Ching Hsu +13 more
semanticscholar +1 more source
Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer [PDF]
, 2014 Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP).
Jason Trubiano +11 more
core +1 more source
Ventilator-associated pneumonia after elective cardiac surgery caused by Pneumocystis jirovecii [PDF]
, 2014 Ventilator-associated pneumonia is a severe complication among patients undergoing cardiac surgery. Although hospital-acquired bacterial pathogens, often multidrug resistant, are the most frequent cause, non-bacterial atypical and opportunistic agents ...
Zamorano, Aníbal +5 more
core +3 more sources